Last reviewed · How we verify
NF-kappaB Decoy
At a glance
| Generic name | NF-kappaB Decoy |
|---|---|
| Sponsor | Anesiva, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NF-kappaB Decoy CI brief — competitive landscape report
- NF-kappaB Decoy updates RSS · CI watch RSS
- Anesiva, Inc. portfolio CI